Regeneron and Sanofi drug extends survival in type of lung cancer - STAT

Regeneron and Sanofi drug extends survival in type of lung cancer - STAT

STAT Plus: Immunotherapy from Regeneron and Sanofi extends survival in non-small cell lung cancer

By MATTHEW HERPER

ERICA YOON FOR STAT

An immunotherapy from the drug firms Regeneron and Sanofi extended survival in previously untreated patients with non-small cell lung cancer.

READ MORE